{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:52:01Z","timestamp":1792000321281,"version":"4.4.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100013420","name":"Tsumura and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013420","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04959-w","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:23:31Z","timestamp":1791998611000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal plasma phosphorylated neurofilament-heavy chain levels in oxaliplatin-induced peripheral neuropathy: a prospective multi-institutional exploratory study"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0776-6434","authenticated-orcid":false,"given":"Yoshiharu","family":"Motoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0596-3423","authenticated-orcid":false,"given":"Katsunori","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7120-2425","authenticated-orcid":false,"given":"Masatomo","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4716-323X","authenticated-orcid":false,"given":"Tsuyoshi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1064-7591","authenticated-orcid":false,"given":"Shingo","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6167-9705","authenticated-orcid":false,"given":"Naohisa","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0893-6706","authenticated-orcid":false,"given":"Yoshinori","family":"Munemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4034-1945","authenticated-orcid":false,"given":"Akihito","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the NYX Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"issue":"6","key":"4959_CR1","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3322\/caac.21204","volume":"63","author":"SB Park","year":"2013","unstructured":"Park SB, Goldstein D, Krishnan AV et al (2013) Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 63(6):419\u2013437. https:\/\/doi.org\/10.3322\/caac.21204","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"4959_CR2","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ana.24951","volume":"81","author":"NP Staff","year":"2017","unstructured":"Staff NP, Grisold A, Grisold W, Windebank AJ (2017) Chemotherapy-induced peripheral neuropathy: A current review. Ann Neurol 81(6):772\u2013781. https:\/\/doi.org\/10.1002\/ana.24951","journal-title":"Ann Neurol"},{"key":"4959_CR3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/nrneurol.2010.160","volume":"6","author":"G Cavaletti","year":"2010","unstructured":"Cavaletti G, Marmiroli P (2010) Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol 6:657\u2013666. https:\/\/doi.org\/10.1038\/nrneurol.2010.160","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"4959_CR4","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1007\/s00520-021-06509-x","volume":"30","author":"AA Argyriou","year":"2022","unstructured":"Argyriou AA, Karteri S, Bruna J et al (2022) Serum neurofilament light chain levels as biomarker of paclitaxel-induced cognitive impairment in patients with breast cancer: a prospective study. Support Care Cancer 30(2):1807\u20131814. https:\/\/doi.org\/10.1007\/s00520-021-06509-x","journal-title":"Support Care Cancer"},{"issue":"6","key":"4959_CR5","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s00520-026-10690-2","volume":"34","author":"P Alberti","year":"2026","unstructured":"Alberti P, Faithfull S, Argyriou AA et al (2026) Serum neurofilament light chain (sNFL) as a predictive biomarker for chemotherapy-induced peripheral neurotoxicity (CIPN): consideration of current evidence, validation steps, and barriers to CIPN biomarker implementation in clinical practice \u2014 a narrative review. Support Care Cancer 34(6):508. https:\/\/doi.org\/10.1007\/s00520-026-10690-2","journal-title":"Support Care Cancer"},{"issue":"4","key":"4959_CR6","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s11095-026-04053-z","volume":"43","author":"EIK Ibrahim","year":"2026","unstructured":"Ibrahim EIK, Girdenyt\u00e9 M, Hu Y et al (2026) Evaluation of sNfL as a biomarker for paclitaxel-induced peripheral neurotoxicity through an Integrated PKPD Model. Pharm Res 43(4):1071\u20131088. https:\/\/doi.org\/10.1007\/s11095-026-04053-z","journal-title":"Pharm Res"},{"key":"4959_CR7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/1744-8069-5-66","volume":"5","author":"SM Jamieson","year":"2009","unstructured":"Jamieson SM, Subramaniam J, Liu JJ, Jong NN, Ip V, Connor B, McKeage MJ (2009) Oxaliplatin-induced loss of phosphorylated heavy neurofilament subunit neuronal immunoreactivity in rat DRG tissue. Mol Pain 5:66. https:\/\/doi.org\/10.1186\/1744-8069-5-66","journal-title":"Mol Pain"},{"key":"4959_CR8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.cca.2013.06.019","volume":"424","author":"JY Cai","year":"2013","unstructured":"Cai JY, Lu C, Chen MH, Ba HJ, Chen XD, Lin JH, Sun J (2013) Predictive value of phosphorylated axonal neurofilament subunit H for clinical outcome in patients with acute intracerebral hemorrhage. Clin Chim Acta 424:182\u2013186. https:\/\/doi.org\/10.1016\/j.cca.2013.06.019","journal-title":"Clin Chim Acta"},{"issue":"3","key":"4959_CR9","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1152\/jn.00398.2021","volume":"127","author":"I Heckler","year":"2022","unstructured":"Heckler I, Venkataraman I (2022) Phosphorylated neurofilament heavy chain: a potential diagnostic biomarker in amyotrophic lateral sclerosis. J Neurophysiol 127(3):737\u2013745. https:\/\/doi.org\/10.1152\/jn.00398.2021","journal-title":"J Neurophysiol"},{"key":"4959_CR10","doi-asserted-by":"publisher","first-page":"e0196","DOI":"10.1097\/MD9.0000000000000196","volume":"3","author":"Y Motoo","year":"2022","unstructured":"Motoo Y, Shinozaki K, Takagi T et al (2022) Randomized controlled trial of the significance of combined use with ninjin\u2019yoeito in CapeOX plus bevacizumab therapy (NYX study). Med Case Rep Study Protocols 3:e0196. https:\/\/doi.org\/10.1097\/MD9.0000000000000196","journal-title":"Med Case Rep Study Protocols"},{"key":"4959_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S2095-4964(17)60338-7","volume":"15","author":"Y Motoo","year":"2017","unstructured":"Motoo Y, Hakamatsuka T, Kawahara N et al (2017) Standards of reporting Kampo products (STORK) in research articles. J Integr Med 15:182\u2013185. https:\/\/doi.org\/10.1016\/S2095-4964(17)60338-7","journal-title":"J Integr Med"},{"issue":"4","key":"4959_CR12","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ctrv.2008.01.003","volume":"34","author":"AA Argyriou","year":"2008","unstructured":"Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP (2008) A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 34(4):368\u2013377. https:\/\/doi.org\/10.1016\/j.ctrv.2008.01.003","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"4959_CR13","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.3390\/cancers12061370","volume":"12","author":"G Cavaletti","year":"2020","unstructured":"Cavaletti G, Marmiroli P (2020) Management of Oxaliplatin-induced peripheral sensory neuropathy. Cancers (Basel) 12(6):1370. https:\/\/doi.org\/10.3390\/cancers12061370","journal-title":"Cancers (Basel)"},{"issue":"2","key":"4959_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s40487-021-00168-y","volume":"9","author":"J Burgess","year":"2021","unstructured":"Burgess J, Ferdousi M, Gosal D et al (2021) Chemotherapy-induced peripheral neuropathy: Epidemiology, pathomechanisms and treatment. Oncol Ther 9(2):385\u2013450. https:\/\/doi.org\/10.1007\/s40487-021-00168-y","journal-title":"Oncol Ther"},{"key":"4959_CR15","doi-asserted-by":"publisher","first-page":"115535","DOI":"10.1016\/j.biopha.2023.115535","volume":"167","author":"D Balayssac","year":"2023","unstructured":"Balayssac D, Pereira B, Descoeur J et al (2023) Plasma neurofilament light chain as a biomarker of peripheral neurotoxicity induced by oxaliplatin and paclitaxel in mice: a NeuroDeRisk preclinical study. Biomed Pharmacother 167:115535. https:\/\/doi.org\/10.1016\/j.biopha.2023.115535","journal-title":"Biomed Pharmacother"},{"key":"4959_CR16","doi-asserted-by":"publisher","first-page":"153998","DOI":"10.1016\/j.tox.2024.153998","volume":"510","author":"L Micheli","year":"2025","unstructured":"Micheli L, Balayssac D, Busserolles J et al (2025) Safety biomarkers for peripheral neurotoxicity in rat: a NeuroDeRisk cross-industry collaborative study. Toxicology 510:153998. https:\/\/doi.org\/10.1016\/j.tox.2024.153998","journal-title":"Toxicology"},{"key":"4959_CR17","doi-asserted-by":"publisher","first-page":"1285359","DOI":"10.3389\/fnins.2023.1285359","volume":"17","author":"K Vlasakova","year":"2024","unstructured":"Vlasakova K, Skinner M, Balayssac D et al (2024) Evaluation of biomarkers for peripheral and central nervous system injury in rats: a NeuroDeRisk\/TransBioLine study. Front Neurosci 17:1285359. https:\/\/doi.org\/10.3389\/fnins.2023.1285359","journal-title":"Front Neurosci"},{"key":"4959_CR18","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1186\/s13046-021-02127-x","volume":"147","author":"H Zhang","year":"2021","unstructured":"Zhang H, Deng T, Liu R et al (2021) Cancer-associated fibroblast-promoted VEGFA activates VEGFR2 on cancer cells to induce intratumoral angiogenesis and generate a pro-tumor microenvironment. J Cancer Res Clin Oncol 147:3079\u20133095. https:\/\/doi.org\/10.1186\/s13046-021-02127-x","journal-title":"J Cancer Res Clin Oncol"},{"key":"4959_CR19","doi-asserted-by":"publisher","first-page":"120486","DOI":"10.1016\/j.jep.2025.120486","volume":"354","author":"R Mao","year":"2026","unstructured":"Mao R, Shen J, Wu Y et al (2026) Combined analysis of network pharmacology and transcriptomics deciphers the pharmacological mechanism of Huangqi Guizhi Wuwu decoction attenuates oxaliplatin-induced peripheral neuropathy via regulating Sirt1. J Ethnopharmacol 354:120486. https:\/\/doi.org\/10.1016\/j.jep.2025.120486","journal-title":"J Ethnopharmacol"},{"key":"4959_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/rapm-2024-106229","author":"RS D\u2019Souza","year":"2025","unstructured":"D\u2019Souza RS, Wilson RE, Abrego-Garcia P et al (2025) Prevalence, risk factors, and characteristics of chronic painful chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Reg Anesth Pain Med. https:\/\/doi.org\/10.1136\/rapm-2024-106229","journal-title":"Reg Anesth Pain Med"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04959-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04959-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04959-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:23:32Z","timestamp":1791998612000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04959-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4959"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04959-w","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"25 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y. Mo. has received lecture fees from Tsumura & Company. N. Y. has received research grants and lecture fees from Tsumura & Company. S. I. has received lecture fees from Tsumura & Company. All other authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"120"}}